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Background: Dozens of randomized controlled trials (RCTs) and meta-analyses have demonstrated the efficacy of
repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder (MDD) treatment, but there has not
been a meta-analysis report which evaluates the efficacy and tolerability of rTMS used as an augmentative strategy
for antidepressants in treatment-resistant depression (TRD) treatment. We thus conducted this meta-analysis, aimed
at clarifying whether rTMS enhances the efficacy of TRD.
Methods: We searched MEDLINE and Cochrane Central Register of Controlled Trials for RCTs for studying the
efficacy of rTMS versus (vs) sham condition when combined with antidepressants in TRD treatment, and screened
the references of the previous meta-analysis about the rTMS for MDD treatment. Response rates and NNT were
chose as the primary outcomes, and remission rates, change from baseline of HAMD scores, dropouts were used as
secondary outcomes. For dichotomous data, an intention-to-treat analysis principle was applied; for continuous
data, we calculated the standard mean difference between groups with a random-effect model. Sensitivity analysis
was done to explore the source of heterogeneity and the factors which potentially impact the efficacy.
Results: Seven RCTs were finally included in the meta-analysis. The total sample size was 279, with 171 in the rTMS
group and 108 in the sham group. The pooled response and remission rate for the rTMS and sham group was
46.6% and 22.1%, respectively; the pooled odds ratio (OR) was 5.12 [95% confidence interval (CI) 2.11-12.45, z = 3.60,
p = 0.0003, and the associated number needed to treat (NNT) was 3.4. rTMS group achieved a significant reduction
of HAMD score than the sham group, the pooled SMD of change from baseline was 0.86 [95% confidence interval
(CI) 0.57-1.15, z = 5.75, p < 0.00001]. Because of the small number of included RCTs, the preplanned sensitivity and
subgroup analyses were finally abandoned. The dropouts in both groups were relatively low, indicating the high
acceptability of rTMS.
Conclusions: For TRD patients, augmentative rTMS after the failure of medications significantly increases the effect
of antidepressants, and rTMS was a safe strategy with relatively low adverse events and low dropout rate,
suggesting that augmentative rTMS is an effective intervention for TRD.
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Depression is a global severe disease. In a report of world
health organization (WHO) [1], MDD ranked thirdly in
global disease burden in 2004 and ranked firstly in moder-
ate and high income countries. Unfortunately, even under
the guidelines of the most competent specialists, more
than 30% of patients cannot achieve a clinical response
to an antidepressant regimen or psychotherapy [2]; these
patients, which are called treatment-resistant depression
(TRD) patients, exerted extremely severe burden on them-
selves and their families. So the treatment of TRDs has be-
come one of the most important and pressing problem in
psychiatry. With the development of neuroscience and
psychiatry, we are now able to treat some TRDs with some
physical method, such as electroconvulsive therapy (ECT),
repetitive transcranial magnetic stimulation (rTMS) and
transcranial direct current stimulation tDCS). Among
these methods, ECT is the oldest and most effective while
often criticized by the adverse effects of seizure induction
and cognitive side effects [3,4], and patients who accepted
ECT treatment often have to bear the stigma on this ther-
apy [5].the limitations of ECT has resulted great interest
in the two newly non-invasive neuromodulation methods:
rTMS and tDCS, which are both of relatively low adverse
effects and similar magnitude of antidepressant effects
compared with antidepressant drugs [6].
rTMS utilizes an electromagnet that generates local
magnetic field pulses to modulate brain functions. It is
believed that rTMS modulates the activity of local neural
circuits by decreasing or increasing the excitability of cor-
tical neurons, depending on the parameters of stimulation.
Usually, frequency higher than 5Hz is considered to in-
crease cortical excitability and frequency lower than 1Hz
decrease [7,8]. In view of this function, researchers have
studied the efficacy of rTMS on different psychiatric disor-
ders, such as schizophrenia and depression, based on the
hypothesis of alleviating psychiatric symptoms by modu-
lating local brain activity. In 1995 George et al. [9] firstly
tried to apply rTMS in the treatment of MDD. After that,
numerous literatures about the efficacy of rTMS on MDD
have been published. In these studies, the parameters of
rTMS were most commonly set as high frequency stimu-
lation focused on the left dorsal lateral prefrontal cortex
(LDLPFC) and low frequency on the right dorsal lateral
prefrontal cortex (RDLPFC) [10].
At present, several meta-analyses [11-26] have indicated
that rTMS is effective for MDD patients. But most studies
had focused on both treatment-resistant and non-resistant
patients and had chosen continuous data, namely, change
from baseline of HAMD or MADRS scores as the primary
outcome except for the study reported by Lam et al. [19],
which focused on the treatment-resistant depression pa-
tients and chose dichotomous data, such as response rates
and remission rates as the primary outcomes. The formerkind of data tends to reserve the information of each RCT
as much as possible, while the latter is easier for doctors
and patients to understand. Nevertheless, the study by
Lam et al. contained unexpected high heterogeneity, and
included RCTs that designed rTMS as either monotherapy
or augmentation to antidepressants, which may be on sus-
picion of mixing studies of great heterogeneity together.
In view of the above disadvantages of the previous meta-
analyses, we designed this meta-analysis focused on RCTs
which studied the efficacy of rTMS used as an augmenta-
tive strategy for antidepressants in treatment-resistant de-
pression. The term “treatment-resistant” in this study is
defined as failing to respond to at least one adequate anti-
depressant treatment [27], the “adequate treatment” means
the medication should have been taken for at least 4 weeks
and the following dose levels were considered adequate:
for tricyclic antidepressants a dose equivalent to impra-
mine 200 mg daily; for SSRIs a dose equivalent to paroxe-
tine 40 mg daily; for venlafaxine 225 mg daily; and for
mirtazapine 60 mg daily [28,29]. And “augmentative” in
this study means either combination of rTMS and stable
antidepressant treatment or simultaneous association of
medication regimen and rTMS. Response rates and NNT
were chosen as the primary outcomes. The baseline of
HAMD scores, remission rates and dropout rates were se-
lected as secondary outcomes. We synthesized the data of
RCTs meeting the inclusion criteria in order to reduce the
complexity and contradictions of different RCTs with rela-
tively small samples collected from available databases and
literatures. Sensitivity and subgroup analyses were con-
ducted further to explore the source of heterogeneity and




We identified articles for inclusion in this meta-analysis
by:
1. Searching MEDLINE and Cochrane Central Register
of Controlled Trials (CENTRAL) from 1 January
1995 to 30 November 2013, using the key words
“transcranial magnetic stimulation”, “depress*”,
“augment*”, “combin*”, “adjunctive”, “resistant” and
”refractory”. We restricted the article type to
“randomized controlled trial” and the language to
“English”.
2. Searching the references of all the previous relevant
meta-analyses [11-26] focused on the efficacy of
rTMS for MDD published earlier than 30 November
2013, as well as of all included RCTs.
The search procedures are described in details in
Additional file 1.
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Studies included in this meta-analysis should satisfy the
following criteria:
1. Study validity: random allocation; double-blind
(i.e. both patients and outcome raters were blind to
the allocation); sham-controlled; rTMS was used as
augmentation to antidepressants;
2. Sample characteristics: subjects should be 18–75
years old with a diagnosis of MDD according to
DSM-IV or ICD-10, comorbidity of psychotic
symptoms was excluded;
3. Efficacy evaluation and outcome reporting: efficacy
should be rated by HAMD (17- or 21-items) or
MADRS, and data are reported in a continuous
(means and standard deviations (SDs) of pre- and
post- treatment HAMD or MADRS scores) or
dichotomous (response, remission and dropout
rates) form able to be synthesized in this
meta-analysis.
4. Articles should be published in English.
Studies were excluded if they were:
(1)Non-RCT design, such as open trials;
(2)Subjects were limited to a specific type of MDD
patients, such as postpartum MDD, old MDD or
secondary depression (i.e., vascular depression);
(3)Sample size smaller than 5 in either rTMS or sham
group;
Data extraction
(1)Sample characteristics: mean age, gender, diagnosis
criteria and definition of treatment resistance;
(2)rTMS-related: frequency, intensity, location,
treatment strategy (number of sessions, duration of
each stimulation and duration of each interval) and
total pulses;
(3)Drug-related: drug strategy (standardized or non-
standardized), washout, types and dosages of each
type;
(4)Primary outcome measure: number of responders
based on the RCTs’ primary efficacy measure
(defined as ≥50% reduction in post-treatment on the
HAMD or MADRS scores) at the end of blinded
treatment;
(5)Secondary outcome measure: number of remitters
based on the RCTs’ primary efficacy measure
(e.g. 17- or 21-item HAMD scores ≤7 or ≤8,
respectively, or MADRS scores ≤10 [30]) at the
end of blinded treatment, or the means and SDs
of change of 17 or 21-item HAMD or MADRS
scores;(6)Acceptability of treatment: number of dropouts in
rTMS and sham groups in each RCT.
Data synthesis and analysis
This meta-analysis was conducted according to the
Cochrane Handbook for Systematic Reviews of Interven-
tion [31], all statistic work were performed by Review
Manager 5.2 and Excel 2007.
We used a random-effect model because the effcicacy of
rTMS between different RCTs was assumed to be varied
considerably. This model endows small-sample studies
with higher weight and leads to a relatively conservative re-
sult [32]. For dichotomous data, if available, an intention-
to treat analysis was selected. In other words, we included
all dropouts after randomization, because this is closer to
clinical practice. When dropouts were excluded for efficacy
assessment in any individual RCT (e.g. subjects who never
returned for assessment after randomization), they were
considered as non-responders. We calculated the pooled
OR of response rate and associated NNT. As reported in
other studies, an NNT ≤ 10 was considered as clinically
meaningful because such a treatment difference would be
regularly encountered in clinical practice [33]. For continu-
ous data, we calculated standardized mean difference
(SMD) of the baseline HAMD or MADRS scores and
change from baseline of HAMD or MADRS scores after
the blinded treatment between active rTMS and sham
groups. When a study had more than 2 groups, the data of
different active rTMS groups were combined together as
one group (the data were combined only when the active
groups did not show significant difference, if they did, the
RCT were excluded).
Heterogeneity was assessed by chi-square and I-square
statistics [34], which is considered to be an indicator of
study heterogeneity when p value for χ2 was lower than
0.1 or when I2 was higher than 35%. Sensitivity and sub-
group analysis were conducted to determine the po-
tential factors, such as sessions (≤10 or >10), intensity
(≤100% or >100%) or total pulses (≤10000 or >10000),
which may influence the antidepressant efficacy of
rTMS. Nevertheless, because the number of included
RCTs was relatively small, the heterogeneity of studies in
subgroup analysis was considerably high, which lowered
the reliability of the results. Finally, we used funnel plot
and visual inspection to examine the publication bias.
Results
Literature search and screening
All the 7 RCTs [27,30,35-39] included in this meta-
analysis were identified by electronic database searching,
and the hand searching of bibliographies of previous
meta-analyses did not result in additional studies avail-
able for data synthesis; two RCTs [40,41] on rTMS’s aug-
mentative effect for TRD obtained by hand searching
Figure 1 Flowchart of literature search and screening.
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two reports are unable to synthesize in this study. The
process of literature search and screening was shown in
Figure 1 and a detailed description of the process was
available in Additional file 1.
Included studies: main characteristics
All included RCTs [27,30,35-39] used HAMD as a
primary outcome measurement. They all mentioned
randomization, while no one described the scheme of al-
location concealment in details. Three studies [30,38,39]
reported how they guaranteed the blindness of the pa-
tients and the efficacy raters, while the other 4 RCTs
[27,36,37] just mentioned “the patients and raters did
not know which group they were allocated”. The risk of
bias table was shown in Figure 2. All the studies had
applied high frequency (≥5Hz) rTMS on the LDLPFC
except for the study of Garcia-toro et al. [37], which
simultaneously applied high frequency rTMS on the
LDLPFC and low frequency rTMS on the RDLPFC.Figure 2 Risk of bias graph: review authors' judgments about each r
studies.The main characteristics of included RCTs were de-
scribed in Table 1.
Response rates
Six RCTs had reported qualified data about response
rates. As a whole, 68/146 (46.6%) and 15/84 (22.1%) sub-
jects in the active or sham rTMS groups were classified
as responders, respectively. The pooled OR was 5.12
(95% CI 2.11-12.45, z = 3.60, p = 0.0003), implying a
significant difference favoring the active rTMS group
(Figure 3). The risk difference translated into NNT was
3.4, namely, one patient would get clinical response in
every 3.4 patients being treated.
Heterogeneity between RCTs did not exceed that ex-
pected by chance (χ2 = 6.09, p = 0.30, I2 = 18%), meaning
that the variance among the effect sizes was no greater than
that expected by sampling error. The associated Funnel
Plot (Figure 4) is roughly symmetric, please refer to the
Additional file 1.
Change from baseline of HAMD scores
Data relating to change from baseline of HAMD scores
were available from 6 RCTs, with a total of 126 and 87
subjects in the active rTMS and sham group, respec-
tively. The pooled SMD was 0.86 (95% CI 0.57-1.15,
z = 5.75, p < 0.00001), indicating the superiority of active
rTMS in alleviating depression severity compared with
sham rTMS (Figure 5).
Heterogeneity between RCTs did not exceed that ex-
pected by chance (χ2 = 2.67, p = 0.75, I2 = 0%), indicating
that the data were reasonably appropriate for synthesis.
The associated Funnel Plot was approximately symmet-
rical. For the associated funnel plot, please refer to the
Additional file 1.
Acceptability of treatment
All the 7 studies included in this meta-analysis reported
the data of dropouts. In total, 9/171 (5.7%) and 5/108
(5.04%) dropped after the blinded treatment in the active
rTMS and sham groups, respectively. The dropout rates
in both groups were relatively low and had no significantisk of bias item presented as percentages across all included
Table 1 Main characteristics of included RCTs
Study Sample
size (n)

















20 90 10 12000 HAMD-21 2w of an
open trial
Scalp discomfort and slight
headaches








15 100 10 6000 HAMD-21 3w of
follow up
Mild headache; discomfort at
the site of stimulation
19 15 80 6000










10 20,1 110 12000







8 90 15 19200 HAMD-17 9w of
follow up
Reduced sleep length and
greater concentration
difficulties (sham group)
Martinot et al. [39] 16 14 DSM-IV-R MDD&









10 90 10 16000 HAMD-21 N Not mentioned
18 10 90 16000
Bakim et al. [30] 12 12 DSM-IV MDD &








20 80 30 24000 HAMD-17 N Mild headache and mild
discomfort
11 20 100 24000






























Figure 3 Meta-analysis of active rTMS vs sham condition used as an augmentative strategy for antidepressants in treatment-resistant
depression: response rates.
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0.07, z = 0.48, p = 0.63] (because there were no dropouts
in two RCTs [30,37], to enroll the data of the two stu-
dies, we chose RD rather than OR), indicating the rela-
tively low adverse effect and high acceptability of rTMS.
Additionally, the side effects reported by patients were
presented in Table 1. The most frequent reported side
effects were mild headache and discomfort in stimulation
location, the headache and discomfort were commonly
transient and did not differ significantly between
groups, implying the safety of rTMS. For the associ-
ated forest plot and funnel plot, please refer to the
Additional file 1.Remission rate
Only 2 RCTs [30,38] reported the number of remitters at
the end of blinded rTMS treatment, both of them found a
significant difference between the active and sham groups
in achieving remission. For the small number or RCTs,
data were not synthesized. For detailed description, please
refer to the Additional file 1.Figure 4 Funnel plot of standard error by log odds ratio: response rarTMS vs sham group: baseline depression severity
No significant difference were observed in baseline sever-
ity between active and sham rTMS groups, the pooled
SMD was −0.09 [95% CI −0.34-0.17, z = 0.66, p = 0.51],
indicating that the two groups are comparable at base-
line and baseline depression severity cannot be a con-
founding factor of the efficacy. For the associated
forest plot and funnel plot, please refer to the Additional
file 1.Sensitivity and subgroup analyses
We tried to carry out sensitivity and subgroup analyses
to explore the potential confounding factors, such as
number of sessions, intensity and total pulses, and drug
strategy (standardized or non-standardized). However,
because the number of included studies is relatively
low and the heterogeneity between RCTs in subgroups
were very high, the preplanned subgroup analyses
were finally abandoned to avoid the misleading results.
For detailed description, please refer to the Additional
file 1.tes.
Figure 5 Meta-analysis of active rTMS versus sham condition used as an augmentative strategy for antidepressants in treatment-
resistant depression: change from baseline in HAMD scores.
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Two studies [36,37] implemented open intervention
after the blinded treatment. In these follow-up studies,
patients in sham groups who did not achieve response
in blinded treatment were enrolled to receive active
rTMS treatment, both studies reported additional reduc-
tion of HAMD scores reduction after the “subsequent
rTMS treatment”. The other three studies [27,35,38] re-
ported non-interventional observation of the follow-up
efficacy of rTMS., Interestingly, in the study of Chen
et al. [35], augmentative active rTMS didn’t achieve sig-
nificant difference compared to sham condition, while
after 1 month’s follow-up, the active group showed sig-
nificant greater HAMD scores reduction than the sham
group, indicating a lagging efficacy of rTMS treatment,
while in the study of Bretlau et al. [27], the results is in-
verse: rTMS group achieved significant greater HAMD
scores reduction after treatment than the sham group,
while after 9 weeks of follow-up, the difference is no longer
significant between the groups. And the study of Rossini
et al. [38] demonstrated a figure that shows active rTMS
group achieved greater HAMD scores reduction both after
treatment and in the follow-up duration than sham group,
and the follow-up data in this study is not available.
Discussion
To our knowledge, this is the first meta-analysis exploring
the efficacy of augmentative rTMS for TRD. We included 7
RCTs and our results demonstrated that rTMS is signifi-
cantly superior to sham condition in TRD treatment, the
pooled OR was 5.12 (95% CI 2.11-12.45, z = 3.60, p =
0.0003), and the associated NNT was 3.4, indicating a rela-
tively high efficacy of rTMS in TRD treatment. Moreover,
our results showed that patients receiving rTMS treatment
achieved significantly greater decrease in HAMD scores
than those who receiving sham condition (SMD= 0.97,
95% CI 0.64-1.31, z = 6.00, p < 0.00001). Additionally, our
results manifested that the baseline depression severity and
dropout rates of the two groups did not differ significantly.
Although more than 10 meta-analyses about the efficacy
of rTMS on depression had been published, there was
only one meta-analysis [19] focused on the treatment-
resistant patients. Nevertheless, the study by Lam et al.
found a relatively high heterogeneity between the includedRCTs, and this may be due to their enrollment of studies
which used rTMS either as monotherapy or augmentation
to antidepressants. Our results overcome the weakness by
limiting the included studies only to the RCTs using rTMS
as an augmentative strategy. For other meta-analyses, most
of them had chosen change from baseline of HAMD scores
or end-point HAMD scores as the primary outcome assess-
ment, this may facilitate reserving the information of each
individual study, but the outcomes of these studies are usu-
ally complicated and not easy for doctors and patients to
understand. In this study, we provided an easily understood
result by choosing response rate and NNT as the primary
outcomes.
Despite the advantages aforementioned, our study has
some limitations. Firstly, the strict inclusion criteria in this
study may help to reduce heterogeneity and enhance the
reliability of our results, but it may also limit our results
only suitable for the condition of augmentative rTMS for
TRD patients, thus we cannot know the efficacy of rTMS
used as monotherapy for TRD patients or used as aug-
mentative strategy for non-resistant MDD patients from
the results of our study. However, that is not we inten-
tioned to know and previous meta-analyses [14,19,24] had
told us the answers to the above questions. Secondly, the
quality of included RCTs is relatively low. Like other rele-
vant meta-analyses [14,19], most included RCTs in this
study did not report the method of allocation concealment
and implementation and maintenance of blinding, which
may lower the scoring of study quality. Thirdly, as men-
tioned in other meta-analyses and RCTs, the sham condi-
tion used in most studies cannot fully eliminate the
placebo effect [10], because some patients receiving rTMS
treatment can perceive the vibration of electromagnetic
coil while the patients in the sham group cannot experi-
ence the effect. Moreover, the “5-cm” location method is
often criticized for its inaccuracy [42,43], and it is un-
known where is the exact stimulated location. Fourth, the
follow-up duration of included studies was relatively low,
and most studies designed open rTMS treatment in the
follow up period. These factors make it impossible to esti-
mate the median- or long-term naturalistic efficacy of
rTMS. Fifth, as the number of included RCTs was relatively
low, the predetermined subgroup analyses were finally
not successfully conducted for the high heterogeneity.
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and total pulses of rTMS and drug strategy had contrib-
uted to the accuracy of the present results, and it should
be settled by future studies.
Conclusions
This study showed that augmentative rTMS was signifi-
cantly superior to sham condition in TRD treatment, and
the two groups did not differ significantly in dropout rates
or side effects, indicating the advantage of rTMS in the ef-
ficacy and acceptability for clinical treatment of TRD. As
the number of included RCTs was relatively low and the
heterogeneity of RCTs in subgroup analysis is higher than
expected by chance, we did not explore the potential con-
founding factors which may influence the effect of rTMS.
Future studies should have more rigid design, such as
reporting the method of allocation concealment and
blinding in details, carrying out longer non-interventive
follow-up to make clear of long-term efficacy of rTMS,
and improving the design of sham condition to alleviate
placebo effect further. Additionally, combination with
neuroimaging technique for identifying the best stimula-
tion location is expected.
Additional file
Additional file 1: Detailed description of the process and results of
this study.
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